Search

Search Results

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• Cardiovascular Toxicity of CAR-T Cell Therapy: A Literature Review

  Shakhabutdin Murtuzalievich Murtuzaliev, E.Yu. Salakheeva, S.A. Kardovskaya, Yu.Yu. Kirichenko, E.A. Siderko, Yu.N. Belenkov, I.S. Ilgisonis

  404-414

  01.10.2024

• The Role of Polymorphic Variants of Р450 Cytochrome Genes as well as Genes GSTP1 and MDR1 in Toxic Complications of Program Drug Chemotherapy for Classical Hodgkin Lymphoma

  Yana Yurevna Shebunyaeva

  141-153

  01.04.2024

• Cardiovascular Complications of the Immunotherapy of Hematological Malignancies: A Literature Review

  Geliya Rifkatovna Gimatdinova, O.E. Danilova, V.P. Kuzmin, G.I. Davydkin, Yu.V. Kostalanova, D.A. Kudlai, I.L. Davydkin

  407-412

  28.09.2023

• Supportive Therapy in Multiple Myeloma: Practical Recommendations

  Maksim Valerevich Solovev, M.V. Soloveva, L.P. Mendeleeva

  426-448

  28.09.2023

• Cardio-oncology and Oncohematology: Examination Algorithms, Prophylactic and Treatment of Cardiotoxicity, Trends in Rehabilitation

  Elena Ivanovna Emelina, G.E. Gendlin, I.G. Nikitin

  239-261

  01.04.2021

• The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients

  Nadezhda Viktorovna Kurkina, E.A. Repina, N.N. Mashnina

  278-281

  01.07.2019

• Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice

  Vladimir Ivanovich Vorob’ev, V.A. Zherebtsova, E.I. Dubrovin, L.A. Bychenkova, Yu.B. Kochkareva, L.A. Mukha, V.L. Ivanova, N.K. Khuazheva, V.V. Ptushkin

  165-172

  01.04.2019

• Practical Aspects of the Use of Carfilzomib in Multiple Myeloma

  Sergei Vyacheslavovich Semochkin, G.N. Salogub, S.S. Bessmeltsev, K.D. Kaplanov

  21-31

  01.01.2019

• Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

  I.L. Davydkin, Kseniya Viktorovna Naumova, A.M. Osadchuk, I.A. Zolotovskaya, O.E. Danilova, T.Yu. Stepanova, O.V. Tereshina, L.V. Limareva, A.S. Shpigel’, T.P. Kuz’mina

  378-387

  01.10.2018

• Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia

  Anna Grigor’evna Turkina, A.Yu. Zaritskii, V.A. Shuvaev, E.Yu. Chelysheva, E.G. Lomaia, E.V. Morozova, A.K. Golenkov, T.I. Pospelova, O.A. Shukhov, M.S. Fominykh, G.A. Gusarova, L.A. Kuz’mina, A.O. Abdullaev, I.S. Martynkevich

  294-316

  01.07.2017

• Second Generation Tyrosine Kinase Inhibitors and Their Toxicity in Treatment of Patients in Chronic Phase of Chronic Myeloid Leukemia

  N.S. Lazorko, Elza Galaktionovna Lomaia, E.G. Romanova, E.I. Sbityakova, E.R. Machyulaitene, P.A. Butylin, A.Yu. Zaritskii

  302-308

  01.07.2015

• First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors

  Vasilii Anatol’evich Shuvaev, K.M. Abdulkadyrov, I.S. Martynkevich, M.S. Fominykh

  78–83

  01.01.2015

• Management of relapsed and refractory multiple myeloma: literature review and our data. Part III

  S.S. Bessmeltsev

  137-174

  01.04.2014

• Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia

  A.A. Zeifman, E.Yu. Chelysheva, A.G. Tukrina, G.G. Chilov

  16-27

  01.01.2014